৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Products
Payment
Delivery
Maintenance treatment of patients with COPD.
Maintenance treatment of asthma in patients aged 10 years and older.
Limitation of use: Not indicated for relief of acute bronchospasm.
Each dry powder inhaler capsule contains:
Vilanterol 25 mcg (as Vilanterol Trifaratate INN)
Fluticasone Furoate INN 100 mcg or 200 mcg
Umeclidinium 62.5 mcg (as Umeclidinium Bromide INN)
Fluticasone furoate: Corticosteroid with anti-inflammatory effects.
Umeclidinium: Long-acting muscarinic antagonist (anticholinergic) → bronchodilation.
Vilanterol: Long-acting β2-agonist → increases cyclic AMP → relaxes bronchial smooth muscle.
Adults (≥10 years): 1 capsule inhaled once daily at the same time.
Do not swallow capsules. Use only with the inhalation device.
Rinse mouth with water after inhalation to reduce risk of oral candidiasis.
For acute symptoms, use a short-acting β2-agonist.
CYP3A4 inhibitors (e.g., ketoconazole) → ↑ systemic corticosteroid & cardiovascular effects.
MAO inhibitors & tricyclic antidepressants → potentiate vilanterol effects.
Beta-blockers → may reduce bronchodilation.
Diuretics → ↑ risk of hypokalemia.
Other anticholinergics → additive effects, avoid co-administration.
Primary treatment of status asthmaticus or acute COPD/asthma exacerbations.
Severe hypersensitivity to milk proteins or any component.
COPD: URTI, pneumonia, bronchitis, oral candidiasis, headache, back pain, sinusitis, diarrhea, cough.
Asthma: Pharyngitis, viral URTI, bronchitis, rhinitis, influenza, headache, back pain.
Insufficient data in pregnant or lactating women. Use only if benefits outweigh risks.
Not for acute symptom relief.
Risk of pneumonia in COPD patients.
Monitor for oral candidiasis.
Use cautiously in cardiovascular disease, urinary retention, seizures, thyroid disorders, diabetes, ketoacidosis.
Children & Adolescents (<17 years): Not established.
Elderly: No dosage adjustment required, but monitor sensitivity.
Renal/Hepatic impairment: Not studied.
No clinical trial data available.
Combined bronchodilator (LABA + LAMA + ICS).
Store in a cool, dry place.
Avoid direct sunlight and heat.
Keep out of reach of children.





N/A
N/A





